Cardio Diagnostics (CDIO) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Myriad Genetics is the larger company by market cap ($409.4 million vs $5.8 million), about 70.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CDIO | MYGN |
|---|---|---|
| Share price | $1.96 | $4.28 |
| Market cap | $5.80M | $409.38M |
| 1-day change | -2.00% | 0.00% |
| YTD return | — | -30.41% |
| 1-year return | — | -43.16% |
| 5-year return | — | -86.52% |
| EPS (TTM) | $-2.91 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.91 | $8.59 |
| 52-week low | $0.97 | $2.74 |
| Distance from 52-week high | -75.22% | -50.17% |
| Average volume | 55.78K | 2.01M |
| Shares outstanding | 2.96M | 95.65M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Myriad Genetics is about 70.6 times larger than Cardio Diagnostics by market value ($409.38M vs $5.80M).
CDIO vs MYGN FAQ
Which is bigger, Cardio Diagnostics or Myriad Genetics?
Myriad Genetics (MYGN) is larger, with a market capitalization of $409.38M compared with $5.80M for Cardio Diagnostics (CDIO).
Are Cardio Diagnostics and Myriad Genetics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.